TRT 'lifetime dependency' claims: what the evidence actually says

What did @chasvitalityrx actually say?

The creator argued that "doing TRT right" means daily microdosed injections plus HCG two to three times weekly, adding up to "nine to ten shots a week." They then pitched their Vitality RX program, which uses enclomiphene, DHEA, and 7-keto DHEA as a needle-free alternative that "stimulates your own testosterone production" without "testicular shutdown" or fertility loss. The framing was explicit: TRT is a last resort, not a first step.

To be clear about what was being sold here: this is a creator affiliated with a named commercial program promoting specific compounds, including enclomiphene and DHEA-based supplements, as a superior alternative to physician-prescribed TRT. That context matters when evaluating the claims.

Does the science back this up?

Partly, but the injection math is cherry-picked and the enclomiphene pitch oversells the evidence. The 9-10 shots per week figure is real but describes a maximalist protocol, not standard of care. The fertility argument has genuine merit. The enclomiphene safety framing needs significant qualification.

Standard TRT protocols typically involve one injection every 7-14 days of testosterone cypionate or enanthate, or daily application of transdermal gel. Daily subcutaneous microdosing exists and some clinicians prefer it for hormonal stability, but it is one option among many, not the default. A 2020 review by Ramasamy et al. in Therapeutic Advances in Urology confirmed that weekly or biweekly injections remain the most commonly prescribed approach in clinical practice.

On fertility: the creator is right that exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH, FSH, and intratesticular testosterone, which impairs spermatogenesis. HCG co-administration is a legitimate clinical strategy to mitigate this. That part is accurate.

Enclomiphene citrate is a selective estrogen receptor modulator that increases endogenous LH and FSH. Early trials, including Wiehle et al. (2014, Andrology), showed it raised testosterone and preserved semen parameters better than topical testosterone in secondary hypogonadism. But it is only FDA-approved for secondary hypogonadism, not primary testicular failure, and long-term safety data remain limited compared to TRT.

What did they get wrong (or right)?

They got the fertility biology right and the injection-burden framing wrong by design. The 9-10 shot figure is technically reachable if you combine daily subQ testosterone with HCG three times weekly, but presenting this as the only correct way to do TRT is misleading. Gels, patches, and pellets exist. Weekly injections exist. The claim that you are "running a home pharmacy" only holds if you ignore every non-injectable delivery method.

The bigger problem is the phrase "no testicular shutdown" applied to enclomiphene. Enclomiphene works by blocking estrogen feedback at the hypothalamus, prompting the body to produce more LH and FSH. It does not work if the testes cannot respond, meaning primary hypogonadism patients get no benefit. The creator's line that "most guys don't even have true testicular failure" is unverifiable without lab data, and steering someone with primary hypogonadism toward enclomiphene instead of TRT could delay effective treatment.

DHEA and 7-keto DHEA are dietary supplements, not regulated drugs. Evidence for meaningful testosterone elevation from either compound in men with clinical hypogonadism is weak. Labrie et al. (2005, Journal of Steroid Biochemistry and Molecular Biology) found modest androgen effects from DHEA supplementation, but effects in men were inconsistent and not clinically validated as a TRT replacement.

What should you actually know?

TRT is not one protocol. Enclomiphene is a real drug with real evidence, but it is not appropriate for every man with low testosterone. The choice between stimulating your own production versus replacing it from outside depends on why your testosterone is low in the first place.

If you have secondary hypogonadism, meaning your testes can produce testosterone but your brain is not signaling them correctly, enclomiphene and similar SERMs are legitimate clinical options. Multiple studies support their use in this population. If you have primary hypogonadism, your testes cannot respond to LH regardless of how much enclomiphene you take, and TRT is likely necessary.

The creator frames TRT as irreversible. That is an overstatement. Post-TRT testosterone recovery is variable and can take months, but recovery is well-documented, particularly in younger men and those who used TRT short-term. Lipshultz et al. (2014, Asian Journal of Andrology) reviewed recovery timelines and found most men regained baseline function within 6-12 months after discontinuation, though outcomes varied.

Anyone evaluating hormone therapy, whether TRT or enclomiphene-based protocols, should get a full hormonal panel including LH, FSH, total and free testosterone, and SHBG before making any decisions. A commercial program's supplement stack is not a substitute for that workup.